Search for a trial | Research with human participants

2 results

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis

Approved WMOCompleted

The primary objective is to assess the efficacy of nemolizumab (CD14152) compared to placebo in subjects >= 18 years of age with prurigo nodularis (PN) after a 16-week treatment period.

A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis

Approved WMORecruiting

This study has been transitioned to CTIS with ID 2024-514502-31-00 check the CTIS register for the current data. The primary objective is to assess the long-term safety of nemolizumab (CD14152) insubjects with prurigo nodularis (PN).The secondary…